The Scripps Research Institute Appoints Alexandria Real Estate Equities, Inc. CEO Joel Marcus to Board of Directors
LA JOLLA, Calif., May 30, 2017 /PRNewswire-USNewswire/ -- The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, today announced the appointment of Joel S. Marcus to its Board of Directors.
Marcus is Chairman, Chief Executive Officer and Founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office real estate investment trust (REIT) uniquely focused on collaborative life science and technology campuses in the top innovation cluster locations in the United States.
Marcus co-founded Alexandria in 1994 as a startup with a business plan and $19 million in seed capital and has since led its growth into an investment-grade rated S&P 500 company. Alexandria has a total market capitalization of approximately $15 billion and a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland and Research Triangle Park.
"Joel's professional experience and business leadership add to the expertise of our current board members," said Peter G. Schultz, Ph.D., President of TSRI and the California Institute for Biomedical Research (Calibr). "His creativity, insight and commitment to research and public health will be invaluable in our efforts to create a new model for funding basic and translational research in the nonprofit sector. We are thrilled to welcome him to the board."
"TSRI is a world-class biomedical science research and discovery Institute," said Marcus. "I am honored to join the TSRI board and look forward to helping the Institute achieve its goals of translating new scientific breakthroughs into life-saving medicines under the visionary leadership of Pete Schultz."
In addition to his work in life science real estate, Marcus is the founder of Alexandria Venture Investments, which focuses on investing in the biopharmaceutical, diagnostic, research tools, agtech, digital health and technology sectors. He also co-founded the Alexandria Summit, an annual invitation-only meeting that convenes the world's foremost thought leaders from the pharmaceutical, biotechnology, agribusiness, technology, medical, academic, venture capital, philanthropic, patient advocacy and government communities to address the most critical challenges in global healthcare, agriculture and the environment.
Marcus serves on the boards of directors for several biotechnology companies, including the Accelerator Corporation (which he co-founded), AgTech Accelerator Corporation, for which he serves as chairman, Atara Biotherapeutics and Intra-Cellular Therapies. He also serves on the boards of the Biotechnology Innovation Organization (BIO) and the Foundation for the National Institutes of Health (FNIH).
Marcus earned his undergraduate and Juris Doctor degrees from the University of California, Los Angeles and was a recipient of the Ernst & Young Entrepreneur Of The Year Award (Los Angeles – Real Estate).
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.
Once available to the public, this and other press releases are posted on the TSRI website at http://www.scripps.edu/news/newsreleases.html
SOURCE The Scripps Research Institute
Share this article